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Abstract: Here we report a novel microelectrode array recording approach to measure tonic (resting)
and phasic release of dopamine (DA) in DA-rich areas such as the rat striatum and nucleus accumbens.
The resulting method is tested in intact central nervous system (CNS) and in animals with extensive loss
of the DA pathway using the neurotoxin, 6-hydroxyDA (6-OHDA). The self-referencing amperometric
recording method employs Nafion-coated with and without m-phenylenediamine recording sites
that through real-time subtraction allow for simultaneous measures of tonic DA levels and transient
changes due to depolarization and amphetamine-induced release. The recording method achieves
low-level measures of both tonic and phasic DA with decreased recording drift allowing for enhanced
sensitivity normally not achieved with electrochemical sensors in vivo.
Keywords: dopamine; sensor; microelectrode array; brain
1. Introduction
Dopamine (DA) serves as a principle neurotransmitter for essential brain pathways that regulate
affect, cognition, movement, and reward [1]. Analytical approaches for the detection and quantification
of extracellular levels of brain DA have been of the utmost importance for elucidating its role as
a modulatory neurotransmitter and for advancing our understanding of how brain DA systems
impact ongoing behavior [2,3]. Extracellular DA is present in both synaptic and extrasynaptic
pools, which enables differential modulation of pre- and postsynaptic neuronal signaling [4].
Following activity-dependent release, diffusion mediates spillover of synaptic DA into extrasynaptic
pools where DA transporters (DATs) are involved in “regulating the sphere of influence and lifetime of
released DA beyond a synapse [5].” However, current analytical techniques are unable to measure both
tonic and phasic levels of DA simultaneously and, thus, require the use of a complementary approach
to investigate the “missing” component of extracellular neurotransmitter dynamics. In turn, there is
a need for the effective simultaneous measure and quantitation of synaptic and extra-synaptic DA
levels using neurochemical methods that combine real-time monitoring with high spatial-temporal
resolution and sensitivity.
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Microdialysis sampling coupled with powerful analytical technologies has been the conventional
approach for quantifying extracellular neurotransmitter levels in vivo. Once collected, dialysate samples
are processed with separation analytics like high-performance liquid chromatography (HPLC),
providing measurements with excellent chemical selectivity and sensitivity while affording
the opportunity to measure multiple analytes for both acute and chronic in vivo studies [6].
Although high-level chemical selectivity and sensitivity measures have become hallmarks of such
strategies, the low-level spatial-temporal resolution of sampling continues to generate curiosity
regarding the missed neurochemical dynamics that occur between the large inter-sample intervals
(typically 10 min) while spurring controversy as to which extracellular pool of neurotransmitters is
being sampled [7,8]. While sampling rates have continued to undergo refinement towards improving
temporal resolution (e.g., up to 1 sample per 10 s), second-by-second or sub-second monitoring has
not hitherto been achieved [6,9]. Microdialysis probes typically have an active length of 1–4 mm with
tip diameters of 0.2–0.3 mm, which places the sampling resolution of this approach at >0.1 mm3 [6].
Because of its large size, probe-induced tissue damage and neuroinflammation may culminate in
secondary effects on neurotransmitter efflux and resting levels, further complicating the interpretation of
results [10–13]. Thus, despite the tandem use of powerful separation analytical approaches, the low-level
spatial-temporal resolution of microdialysis continues to limit its capabilities for monitoring phasic
neurotransmission in vivo.
In vivo electrochemical approaches have emerged as a complementary collection of techniques
to microdialysis as they “provide answers that are not presently accessible by microdialysis or any
other measurement technique [11].” For example, in vivo electrochemistry has been instrumental to
identifying the presence of spontaneous DA release and regulation of DAT-mediated clearance of
DA [14–18]. Electrochemical sensors are designed for use in freely moving behavioral recordings where
higher resolution is necessary to capture transient DA events. While the chemical selectivity achieved
with powerful separation technologies is irrefutable, the spatial-temporal resolution of electrochemical
techniques greatly exceeds that of microdialysis probes and, thus, enables sub-second measures with
an electrode diameter of 5–200 µm [19]. Importantly, smaller sized electrochemical electrodes produce
less tissue responsiveness and damage post-implantation in the brain [20,21]. Although advances
in electrochemical approaches have opened up new avenues in the area of in vivo neurotransmitter
monitoring including 3D printed carbon electrodes, submicron sized cavity carbon-nanopipette
electrodes, sub-millisecond resolution measuring DA over months, and optogenetic stimulation,
the most significant shortcoming of these approaches for measures of extracellular DA continues to be
the inability to resolve resting neurotransmitter levels [14,22–25].
Here, we describe the development and implementation of ceramic-based microelectrode arrays
(MEAs) for intracranial monitoring of tonic and phasic DA neurotransmission by: (1) demonstrating the
ability of MEAs to measure DA in vitro and in vivo with constant potential amperometry; (2) discussing
in vivo testing through proof-of-concept experiments using normal and denervated striatum in
anesthetized rats; and (3) introducing new developments for the measurement of brain DA through
a conformal MEA design that enable the real-time, simultaneous monitoring of DA from multiple
depths in the rat brain.
2. Materials and Methods
2.1. Reagents
Unless stated otherwise, laboratory chemicals were purchased from Fisher Scientific (Waltham,
MA, USA) or Sigma Aldrich (St. Louis, MO, USA).
2.2. Experimental Subjects
Male Sprague–Dawley rats (10–12 weeks old; Harlan Laboratories, Inc.; Indianapolis, IN, USA)
were individually housed on a 12 h light/dark cycle with ad libitum access to food and water.
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Animals were acclimated ≥1 week before any experiment. All procedures involving the use of animals
were carried out in accordance with the National Institutes of Health Guide for the Care and Use of
Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of the
University of Kentucky (IACUC Identification Number: 2019-3387).
2.3. Dopamine (DA) Lesions
Striatal DA was depleted by unilateral infusion of 6-hydroxydopamine (6-OHDA) into the
medial forebrain bundle (MFB), which causes an extensive and non-recoverable lesion to the DA
neurons [26,27]. Animals were anesthetized by inhalation of 1.5–3% isoflurane (Isothesia™, Butler;
Dublin, OH, USA) and, once stable, were administered Rimadyl® (5 mg/kg, intraperitoneal injection
(i.p.)) for pre-operative analgesia. Body temperature was maintained using a recirculating water
blanket (Gaymar® Industries, Inc.; Orchard Park, NY, USA). The right MFB was infused with 6-OHDA
(3.0 µg/µL) or vehicle—sterile saline containing 0.02% ascorbic acid (AA)—at a flow rate of 1 µL/min
through a 26 s gauge GASTIGHT Hamilton syringe (Hamilton Company; Reno, NV). The delivered
volumes and stereotaxic coordinates were 2.5 µL at tooth bar (TB): −2.3 mm, anterior-posterior (AP):
−4.4 mm, medial-lateral (ML): −1.2 mm, dorsal-ventral (DV): −7.8 mm and 2.0 µL at TB: +3.4 mm,
AP: −4.0 mm, ML: −0.8 mm, DV: −8.0 mm. The AP and ML stereotaxic coordinates were taken
with respect to Bregma and DV coordinates were determined relative to the brain surface for all
stereotaxic surgeries [28]. Following infusion, the syringe was left in place for 2.5 min before being
slowly retracted.
2.4. Microelectrode Array (MEA) Preparation
The photolithographic fabrication of ceramic MEAs has previously been described in detail [27,29].
All electrochemical procedures were carried out using the FAST-16 mkII recording system and software
(Quanteon, L.L.C.; Nicholasville, KY, USA). The present study used S2 (Side-by-Side 2nd generation,
Figure 1A) and Double-Sided-Pair-Row-8 pairs, conformal DSPR8 (Figure 1B) ceramic-based MEAs
which were obtained from the Center for Microelectrode Technology cost center (University of
Kentucky, Lexington, KY, USA). S2 MEAs, have previously been characterized [25]. These comprised
n = 4 platinum recording sites (15 × 333 µm each) geometrically arranged as two side-by-side pairs
(30 µm between sites within a pair, 100 µm separation between pairs) [30]. The newly designed,
conformal DSPR8 MEAs comprised n = 8 platinum recording sites (50 × 100 µm each) geometrically
arranged as four vertically aligned pairs (100 µm between sites within a pair) with differential
spacing between pairs to enable simultaneous electrochemical recordings at multiple brain depths
along the dorsal-ventral plane (Figure 1B). All MEAs were prescreened to select electrodes that had
recording site sensitivities for analytes that were within +/− 10% standard deviation (SD) to achieve
the analytical performance necessary for the studies. On the day before electrochemical recordings,
all Pt recording sites were coated with the anionic polymer Nafion® (Figure 1A,B), which repels
negatively charged interferents such as AA and 3,4-dihydroxyphenylacetic acid (DOPAC), as previously
described [29,31,32]. One site within each pair of S2 MEAs (Figure 1A) or the upper recording site of
each pair of the DSPR8 MEAs (Figure 1B) was then selectively electroplated with m-phenylenediamine
(m-PD), a size exclusion barrier that blocks DA and other large molecules from reaching the Pt recording
sites [33]. m-PD was selectively electrodeposited onto individual platinum recording sites as previously
described [34]. Following coating with Nafion® and differential electroplating with m-PD, MEA tips
were soaked in phosphate-buffered saline (PBS) at 25 ◦C overnight prior to use to remove excess
m-PD molecules. The final configuration of S2 (Figure 1A) and DSPR8 (Figure 1B) MEAs consisted of
Nafion®-only sites (i.e., DA sites) and Nafion®-coated + m-PD electroplated sites (i.e., sentinel sites).
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Figure 1. Microelectrode array (MEA) design and function as configured for dopamine (DA) 
measurement. Photomicrographs and corresponding schematics of Nafion® -coating and selective 
electrodeposition of m-phenylenediamine (m-PD) for a (A) 4-channel S2 MEA (333 × 15 micron pairs) 
and (B) 8-channel DSPR8 MEA with reaction schemes are shown. The distance between recording 
pairs is also shown for both MEAs. 
2.5. In Vitro Microelectrode Array Electrochemistry 
On the day of in vivo electrochemical recordings, MEAs were individually calibrated in 40 mL 
of stirred 25 °C PBS (0.05 M; pH 7.4) as previously described [30]. Constant potential amperometry 
was used for all electrochemical experiments. A +0.35 V potential vs. a RE-5B Ag/AgCl reference 



















































































Figure 1. icr l t rr ( ) design and function as configured for dopamine (DA)
measurement. Photomicrographs and cor esponding schematics of Nafion®-coating and selective
electrodeposit on of m-phenylenediamine (m-PD) for a (A) 4-chan el S2 MEA (3 × 15 micron pairs)
and (B) 8-channel DSPR8 MEA with reaction schemes ar shown. The distance between recording pairs
is also shown for both MEAs.
2.5. In Vitro Microelectrode Array Electrochemistry
On the day of in vivo electrochemical recordings, MEAs were individually calibrated in 40 mL
of stirred 25 ◦C PBS (0.05 M; pH 7.4) as previously described [30]. Constant potential amperometry
was used for all electrochemical experiments. A +0.35 V potential vs. a RE-5B Ag/AgCl reference
(Bioanalytical Systems; West Lafayette, IN, USA) was applied at a frequency of 1 Hz (S2) or 4 Hz
(DSPR8); 1 Hz and 4 Hz data were comparable. After establishing a stable baseline, interferent(s) and
analyte additions were made to the stirred solution. Unless stated otherwise, AA (250 µM) and three
additions of DA (2 µM increments) served as the interferent and analyte, respectively.
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2.6. In Vivo Microelectrode Array Electrochemistry
Surgical procedures for in vivo electrochemical studies were carried out as previously described [35,36].
Animals were anesthetized with urethane (1.25 g/kg, i.p.), and body temperature was maintained
using a re-circulating water blanket. A Ag/AgCl reference wire was placed in the superficial cortex
through a hole drilled caudal to the MEA implantation site. Calibrated S2 MEAs were first targeted to
the primary motor cortex using the following coordinates: AP: +1.0 mm, ML: ±2.5 mm, DV: −2.0 mm.
After establishing a baseline signal in cortex, S2 MEAs were lowered ventrally with the aid of a
microdrive to the dorsal striatum (dSTR) to a new DV coordinate of −3.5 mm. DSPR8 MEAs were
implanted using the following coordinates: AP: +1.0 mm, ML: −2.5 mm, DV: −6.3 mm. In all cases,
the tip of the MEA device was lowered to the indicated DV coordinate with respect to the brain surface.
Once implanted, saline-soaked cotton balls or gauze were placed around the MEA shank to keep the
brain surface moist. For some studies, micropipettes were affixed to S2 MEAs (aligned in the center
between upper and lower recording pairs) for the local delivery of isotonic KCl (120 mM KCl, 20 mM
NaCl, 2.5 mM CaCl2; pH 7.4) as previously described [34]. At the end of in vivo electrochemical
recordings, each animal was sacrificed by decapitation.
2.7. Determination of Striatal DA Tissue Content
The tissue content of DA in the dorsal striatum was determined from normal and 6-OHDA
lesioned animals as previously described [37].
2.8. Data and Statistical Analyses
All data are expressed as the mean ± standard error of the mean (SEM). Means were determined
by summing the individual samples then dividing by the number of samples. Standard deviation was
calculated by taking the square root of the variance. Variance was calculated by averaging the squared
differences from the mean. SEM was calculated by dividing the standard deviation of the samples
by the square root of the sample size. Selectivity, linearity (R2), sensitivity (i.e., DA slope) and limit
of detection (LOD) were calculated for all recording sites as previously described [29]. In the case
of S2 MEAs, self-referencing was used to identify and eliminate interfering signals and background
charging current from the analyte response as previously described [32]. Thus, signals from sentinel
sites were subtracted from those of DA sites of S2 MEAs to yield one self-referenced signal per pair
of platinum recording sites (i.e., the self-referenced signal). Stable baseline recordings were first
obtained from the primary motor cortex (i.e., an area of low DA innervation) in each animal before
recording from the dorsal striatum (i.e., area of high DA innervation) [38,39]. The average current of
the self-referenced cortical signal 1 min prior to relocation to the dSTR was subtracted from each point
of the self-referenced dSTR signal of the same animal to determine the resting DA current.
3. Results
3.1. In Vitro Characterization of MEAs for Measuring DA
The recording properties of 4-channel S2 (Figure 1A) and 8-channel DSPR8 (Figure 1B) MEAs
configured for the measurement of DA were evaluated through in vitro calibrations in PBS (Table 1).
Constant potential amperometry (Eapplied = +0.35 V) was used to measure DA at individual recording
sites over a DA concentration range of 0–6 µM (2 µM increments). Oxidation of DA with the MEA
recording sites occurred at any potential greater than +0.2 V vs. Ag/Ag+ on the MEAs [40]. The applied
potential of +0.35 V was chosen because it achieved a robust DA response while limiting oxidation of
species that could be present like H2O2 or NO that oxidize at higher potentials. Nafion®-coated DA
recording sites on both S2 and DSPR8 MEAs had excellent linearity for DA detection while effectively
maintaining high selectivity ratios for DA over 250 µM challenges of AA (Table 1) or DOPAC (data not
shown). As shown in Table 1, both MEA types demonstrated high-sensitivity measurements of DA
(range, in pA/µM: S2, −5.9 to −121.3; DSPR8, −3.5 to −107.2), nanomolar limits of detection recorded
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without self-referencing subtraction (range, in nM: S2, 2.7 to 430; DSPR8, 1.9 to 100.0) and showed
similar sensitivity per unit area measurements of DA (range, in pA/µM−1/mm−2: S2, −1181 to −24,277;
DSPR8, −696 to −21,437). Importantly, sentinel recording sites (i.e., Nafion®-coated + m-PD) did not
respond to additions of DA or AA. Sensitivity/area is comparable to previous work [29].
Table 1. Recording properties of microelectrode arrays for the measurement of DA.
Electrode Type n Sensitivity (pA/µM) Sensitivity/Area (pA mM−1 mm−2) LOD (nM) R2 Selectivity
S2 23 −42.0 ± 0.0 −8422 ± 954 62.3 ± 21.3 0.976 ± 0.008 1487 ± 194
DSPR8 20 −31.7 ± 7.1 −6349 ± 1423 27.5 ± 5.7 0.965 ± 0.006 2664 ± 358
3.2. Proof-of-Concept for MEA-Based In Vivo Measures of Phasic and Tonic DA Levels
The high level of spatial-temporal resolution imparted by in vivo electrochemical technologies
with microelectrodes has been instrumental to shaping current views of phasic DA neurotransmission
in the areas of release and uptake [11]. The ability of S2 MEAs to measure phasic changes in extracellular
DA was determined in the dSTR of anesthetized rats with and without a 6-OHDA lesion. The in vivo
MEA response was tracked following the local application of DA (100 nL; 200 µM, pH 7.4) in the dSTR
(data not shown). In addition to detecting exogenous DA, MEAs successfully captured active DA
uptake—indicated by the descending portion of the curve. In keeping with previous observations
from our laboratory using carbon fiber microelectrodes, amplitude-matched DA signals were cleared
more slowly in the lesioned vs. non-lesioned dSTR [41]. Figure 2 shows the in vivo MEA response to
repeated applications of KCl (100 nL; 120 mM, pH 7.4) in the dSTR, which stimulates neurotransmitter
release from nerve terminals. Ejection of KCl in the non-lesioned dSTR stimulated endogenous DA
release (peak amplitude in µM: first stimulation, 4.3; second stimulation, 3.1). Importantly, KCl-evoked
DA release in the lesioned dSTR was significantly reduced for both the first and second applications
of KCl (peak amplitude in µM based on the calibration slope calculated in pA/µM: first stimulation,
0.1; second stimulation, 0.05). In addition, while the rat striatum has norepinephrine and serotonin
nerve terminals that can be detected by the MEAs, the KCl-evoked signals are dramatically reduced
in the lesioned striatum showing that the signal recorded is likely predominantly DA. The MEAs
are known to respond to serotonin and norepinephrine in vitro and in vivo, but the levels of these
neurotransmitters in vivo are 40–1000 folds lower than the DA based on the tissue levels of the
monoamines [42]. Collectively, these data support the use of MEAs for traditional measures of in vivo
DA signals.
The inability of in vivo electrochemical techniques to measure tonic DA levels continues to be
a major shortcoming and necessitates that a complementary approach (e.g., microdialysis) be used
to study resting DA levels [7]. While the combined approach escalates the complexity, cost and
commitment to a study, inclusion of one approach and not the other may only be appropriate for
certain experimental designs. MEAs have been routinely utilized to quantify both evoked and resting
glutamate levels in the CNS [30,32–34,43–46]. Therefore, we employed 4-channel S2 MEAs in initial
studies aimed at providing proof-of-concept for measurement of tonic DA levels in the dSTR of
anesthetized rats. Preliminary studies determined that self-referencing alone did not always remove
the intrinsic background current of S2 MEA recording sites in vivo (data not shown). Therefore,
we utilized the small size of the MEA device to record electrochemical signals in brain regions that differ
with regard to dopaminergic innervation—DA innervation is low in the primary motor cortex and high
in the dSTR—in conjunction with the self-referencing approach to establish a baseline electrochemical
signal in the brain microenvironment (Figure 3A). MEAs were first positioned in the cortex, and after
establishing a stable baseline signal (typically ≥90 min), S2 MEAs were lowered ventrally to a final
recording position in the dSTR (Figure 3A). Initially, the self-referenced baseline signal measured by DA
sites appeared to be comparable between the cortex and dSTR (Figure 3B). However, Figure 3B shows
that the dSTR baseline signal is actually greater (i.e., flipped) vs. the cortical baseline signal (in vivo
baseline current, in pA: cortex, 71.7; dSTR, 73.0). Thus, by first recording in the primary motor cortex,
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which is void of DA, the electrochemical current in the dSTR and background electrochemical current of
the brain could be distinguished. We next used these basic principles to measure tonic (i.e., resting) DA
levels in the dSTR of rats with and without a 6-OHDA lesion. Following self-referencing, the cortical
baseline signal was subtracted from the dSTR baseline signal to remove the background electrochemical
current to enable resting DA levels to be quantified. The S2 MEA approach showed a significant 88%
decrease of resting DA levels in the dSTR (in nM: non-lesioned, 19.4 ± 2.1; 6-OHDA, 2.3 ± 1.3 ***;
paired t-test, *** p < 0.001). HPLC confirmed a 99% loss of DA tissue content in the denervated dSTR
(in µg/g of tissue: non-lesioned, 6.3 ± 0.8; 6-OHDA, 0.03 ± 0.002). These low nanomolar levels of
resting DA are consistent with studies using no net flux microdialysis [6,47–50] and the recent square
wave voltammetry study by Taylor et al. [51].Appl. Sci. 2020, 10, x FOR PEER REVIEW 7 of 15 
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cortical baseline was subtracted from the self-referenced baseline signal in dSTR to calculate differences
in resting DA levels between the non-lesioned and 6-OHDA lesioned dSTR. *** p < 0.001, paired t-test.
Note the low nanomolar detected levels of DA by the method. (D) High-performance liquid
chromatography (HPLC) analysis of DA tissue content from non-lesioned and 6-OHDA lesioned dSTR.
*** p < 0.001, paired t-test (n = 5–7).
3.3. Conformal MEAs for In Vivo Measures of DA from Multiple Recording Depths
The proof-of-principle studies outlined above led us to design a novel 8-channel MEA with
differential spacing of platinum recording site pairs to enable simultaneous measures of DA at multiple
recording depths in the rat brain. The single-sided DSPR8 MEA was designed on earlier studies
using S2 MEAs to measure DA. Figure 4A shows the 1–2 mm spacing between recording pairs on
the DSPR8 MEA, which allows, in this case, one pair of sites to record in the primary motor cortex
while the other three more ventral pairs (≥2 mm from the cortical pair) are positioned to record at
multiple depths in the dSTR (1 mm spacing between each pair in the dSTR). Once the tip of the DSPR8
MEA was lowered to the final DV coordinate, the electrochemical signals were allowed to reach a
stable baseline (typically ≥90 min). Figure 4B–D show the self-referenced DA signal at each recording
depth before and after systemic administration of the psychostimulant d-amphetamine (2 mg/kg, i.p.).
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The onset of d-amphetamine changes in DA signaling was quite rapid. In vitro testing showed MEAs
are insensitive to d-amphetamine.
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Figure 4. Conformal MEA design for simultaneous measures of in vivo DA dynamics at multiple
recording depths. (A) Depth profile illustrating location of each MEA pair; (B–D) concentration versus
time plots for subjects 1–3 before and after administration of d-amphetamine (2 mg/kg, i.p.). Time axis
bars are 10 min and concentration axis bars are 1 0 µM.
The effects of the psychostimulant, d-amphetamine, on DA release have been widely characterized
and are a known way to measure non-calcium dependent release of DA [52]. Therefore, we assessed
the effect of systemic administration of d-amphetamine (2 mg/kg, i.p.) on resting levels of DA in the
anesthetized dSTR of rats. d-Amphetamine caused a rapid extracellular increase in DA. Interestingly,
the elevated levels of resting DA were accompanied by DA transients seen more closely in Figure 5,
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which are likely related to the complex actions of d-amphetamine on DA release. The number of spikes
and the amplitudes varied in number and size (range: ~5 nM to 800 nM). Of particular note is that this
pilot study shows the variable response of DA nerve terminals to the d-amphetamine in subregions of
the rat striatum and nucleus accumbens (ventral striatum) of the same animal.
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Figure 5. r plots (A–C) show the self-referenced dopamine peak amplitude at the 3 depths
for subjects 1–3; bar is the average amplitude of the spikes in each region. Lower traces (D–F) are
self-referenced DA co centration versus time plots for the three test subjects f llowing administration
of d-amphetamine. Green arrows indicate the time that the d-amphetamine was administered. Note
the high signal-to- noise of these signals that are not filtered or averaged. Typical detection limits of
these signals, based on a signal-to-noise of 3, typically ranged from 0.3 to 1 nanomolar, rivaling the
recent report of Taylor et al., 2019 [51].
4. Discussion
In vivo monitoring of neurotransmitters in the CNS during the last decade with ceramic-based
MEAs has primarily focused on the measurement and quantification of non-electroactive chemical
species (e.g., glutamate) through enzyme-mediated conversion to an electroactive reporter molecule
(i.e., H2O2) [30,34,43–45]. Undoubtedly, the success of these approaches for the determination of
phasic and tonic neurotransmitter levels, can be directly attributed to the multi-site configuration of
the MEAs [29,32]. More recently, Nafion®-coated MEAs with m-PD electroplated on select platinum
recording sites were used for the measurement of brain nitric oxide [53]. Here, S2 MEAs were
successfully utilized to measure phasic and tonic DA levels in the anesthetized rat dSTR—extending
the abilities of MEA technology for in vivo monitoring. The confirmation of a hypodopaminergic state
in the 6-OHDA lesion model—attenuated DA uptake, impaired evoked release of DA and depleted
resting DA levels—observed with the S2 MEAs provided a sound platform and proof-of-concept for
further exploring the utility of this approach.
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In addition to repelling negatively charged molecules (e.g., AA), thus reducing high-level
background currents in vivo, Nafion® concentrates positively charged molecules (e.g., DA) near the
electrode surface [28,31,32]. During the last decade, the design and fabrication of MEAs has continued
to evolve alongside steps towards understanding the unique performance abilities of the device [54].
When compared with earlier MEA designs, the enhanced performance of the MEA types used here to
measure DA can likely be attributed to improved precision and reproducibility of the Pt recording
sites due to the MEA fabrication process [29]. Subtle differences between individual recording site
performances within a single MEA device, as well as between MEA devices, are not unexpected since
individual pads retain unique physical properties post-fabrication. In this regard, we have recently
shown that the nanostructured surface topography of individual pads contributes to an electroactive
area that is greater than the geometric area [41]. However, dissimilarities regarding the thickness of
Nafion® following dip-coating, which may produce differential diffusion layers, may also contribute
to small differences in the responsiveness of individual recording sites. In addition to confirming the
utility of Nafion® for repelling major CNS interferents, our findings here further support the utility of
m-PD for removing larger organic molecules (e.g., AA), including the analyte of interest (i.e., DA),
for the incorporation of self-referencing approaches [33].
Both Nafion and m-PD were employed on the sentinel recording sites to achieve the self-referencing
configuration to selectively measure resting DA levels This dual-selective layer makes the Pt recording
sites of the MEAs essentially unresponsive to electroactive species that are anionic and larger than
H2O2. When the sentinel signal is subtracted from the Nafion-only site a ‘pure’ catecholamine signal
is achieved. In addition, m-PD can be precisely coated onto recording sites even if they are in close
proximity (within microns) to other sites. The resulting electrode pairs have excellent selectivity over
anionic species such as DOPAC and ascorbate. In addition, they display nanomolar detection limits for
DA which are adequate to measure resting levels. However, the subtraction approach employed in this
study achieved improved baseline stability for long recordings in vivo (>2 h) and had an improved
apparent limit of detection (LOD) that far exceeds standard amperometric recordings with the same
MEAs (Table 1). This is similar to self-referenced in vivo glutamate measures where noise that is present
on both sites is removed [55,56]. Our estimated LOD for the S2 and DSRP8 MEAs, employed using
the self-referencing subtraction approach, ranged from 0.3 to 1 nanomolar, which rivals the recent
report of DA detection by Taylor et al. using square-wave voltammetry [51]. This is seen from the
recordings of d-amphetamine-induced DA transients seen in Figure 5, which required no filtering or
signal averaging. The improved stability and enhanced LOD of the recording are attributed to the “real
time” subtraction of the non-Faradaic background current of the Pt recording pairs that achieves the
measures of resting DA. The improved baseline stability and the enhanced LOD exceed the capabilities
of other amperometric recording methods, warranting further investigation and use.
Amperometric recording methods have always been limited due to the inherent problems of the
current signal being composed of both non-Faradaic, background current and the Faradaic response to
analytes [57]. As such, techniques such as differential pulse voltammetry and chronoamperometry were
developed to minimize the analytical shortcomings of the unpredictability of an electrode’s “double
layer” [57]. The present study employed a novel approach to subtract off the apparent “non-Faradaic”
signals of the recording pads by a real-time subtraction approach that measures the differential response
of two nearly identical recording pads. This approach cannot be readily achieved by hand-fabricated
microelectrodes where the active surface area of the electrode cannot always be predicted from the
geometric area of the surface. By contrast, the MEAs are a microfabricated technology that achieves
precision by methods used in the microelectronic industry to build microchips. The manufacturing
process achieves a high level of precision and the MEAs are sorted for their analytical response to
achieve precision so that in essence the Pt recording sites are nearly identical. Thus, in contrast to
many microelectrode technologies, the active recording surfaces are highly reproducible and the active
recording area of the electrode is proportional to the surface area. We stress that the differential recording
method described in this paper will only work with MEAs that have a very high level of recording site
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precision. In this study, conformal MEAs were used to compare real-time DA levels from multiple
recording depths in vivo within the same animal following systemic administration of d-amphetamine.
D-amphetamine has been extensively studied and is known to produce a non-calcium-dependent release
of DA through its interaction with the dopamine transporter (DAT) located on the DA presynaptic
terminal [52]. Importantly, DA is released through the reverse transport of DAT [21]. Our study
demonstrated such release in multiple areas of the rat striatum, yielding signals that contained both
slower DA release and evidence of transient DA signals of varying amplitudes and time courses in
some brain regions. Galli and coworkers using electrophysiological methods to study DAT have shown
that d-amphetamine can change the probability of d-amphetamine-induced DA release through the
DAT by a shuttle carrier vs. pore like model [58]. We attribute the more transient spikes of DA release
seen in some to the rat brain areas to be due to enhanced pore function of the DAT. This is an exciting
hypothesis that needs to be further explored.
5. Conclusions
The present study has demonstrated that a differential recording method can be employed in
DA-rich areas of the rat striatum and nucleus accumbens to reliably measure tonic (resting) and phasic
DA release with subsecond temporal resolution and a refined spatial resolution dictated by the size of
the MEA Pt recording sites. Proof of concept studies show that the technique can reliably measure
changes in resting levels and transient changes in DA with improved baseline stability and a greatly
enhanced apparent LOD. The use of the DSRP8 MEAs demonstrates that multisite recordings can
be simultaneously made in brain subregions within the same animal. The enhanced stability of the
recording method and the improved LOD of the method is worthy of further exploration.
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